期刊文献+

原发性浆细胞白血病临床特征与最佳治疗方案探讨 被引量:2

下载PDF
导出
摘要 目的:分析探讨原发性浆细胞白血病的临床特征以及最佳治疗方案。方法:选取20例原发性浆细胞白血病患者,对其临床资料进行回顾性分析。结果:常规化疗无法达到长期缓解目的,共9例患者采取常规化疗,其中1例为CR,5例为PR,3例为进展;5例患者采取硼替佐米联合常规化疗,均为PR;3例患者采取化疗联合沙利度胺治疗,其中1例获得CR,2例为PR;3例患者放弃治疗。结论:原发性浆细胞白血病倾向于急性白血病,其预后与患者的生存情况均较差,采取硼替佐米对其进行治疗具有靶向作用,能够积极改善患者的病情,为患者治疗带来希望。硼替佐米联合常规化疗对原发性浆细胞白血病具有较高疗效,值得进一步研究。
作者 杨弘 李云涛
出处 《亚太传统医药》 2013年第3期125-126,共2页 Asia-Pacific Traditional Medicine
  • 相关文献

参考文献5

  • 1王迎,张凤奎,井丽萍,李洋,李刚,薛峰,杨仁池,储榆林.23例原发性浆细胞白血病的临床分析[J].中华血液学杂志,2005,26(1):46-47. 被引量:19
  • 2徐瑞容,陈秀芳,丁润生.原发性浆细胞白血病治疗方案[J].中华血液学杂志,2009,22(8):497-498.
  • 3姜波,王华,刘兵城,等.浆细胞白血病实验室诊断与鉴别研究[J].诊断学理论与实践,2009,7(2):332-333.
  • 4范例权,熊树民.硼替佐米联合化疗及自体移植治疗原发性浆细胞白血病2例并文献复习[J].临床血液学杂志,2()10,23(6):79-80.
  • 5KRUGER WH, KIEFER T, SCHULER F, et al. Complete remission and early relapse of refractory plasma cell leukemia after borterzomib induction and consolidation by HLA mis matched unrelated allogeneic stem cell transplantation]. onkologie, 2010, 30(4): 193-194.

二级参考文献10

  • 1Kyle RA, Maldonado JE, Baynd ED. Plasma cell leukaemia: report on 17 cases. Arch Intern Med, 1974,133:813-818.
  • 2Noel P,Kyle RA. Plasma cell leukaemia:an evaluation of response to therapy. Am J Med, 1987,83:1062-1069.
  • 3Regis C, Daniele S, Reda B, et al. Primary plasma cell leukaemia: a report of 18 cases. Leuk Res, 2001,25:103-107.
  • 4Garcia-Sanz BR, Orfao A, Gonzalez M, et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood, 1999,93:1032-1037.
  • 5Bernasconi C, Castelli G, Pagnucco G, et al. Plasma cell leukaemia:a report of 15 patients. Eur J Haematol,1989,51Suppl:76-77.
  • 6Vela-Ojeda J, Garcia-Ruiz Esparza MA, Rosas-Cabral A,et al. Intermediate doses of melphalan and dexamethasone better than vincrstine,adriamycin, and dexamethasone(VAD) and polychemotherapy for the treatment of primary plasma cell leukemia. Ann Hematol, 2002, 81:362-367.
  • 7Hovenga S, de Wolf JT, Klip H, et al. Consolidation therapy with autologous stem cell transplantation in plasma cell leukemia after VAD,high-dose cyclophosphamide and EDAP courses: a report of three cases and a review of the literature. Bone Marrow Transplant, 1997,20:901-904.
  • 8Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med, 1999,341:1565-1571.
  • 9Hideshima T, Chauhan D, Podar K, et al. Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol,2001,28:607-612.
  • 10Strasser K, Ludwig H. Thalidomide treatment in multiple myeloma.Blood Rev,2002,16: 207 -215.

共引文献18

同被引文献8

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部